NasdaqCM:SLNOBiotechs
Reassessing Soleno Therapeutics (SLNO) Valuation After Wolfe Research’s Confidence Boost and Improving Fundamentals
Soleno Therapeutics (SLNO) just received a meaningful vote of confidence from Wolfe Research, which helped push the stock up about 5% as investors reassess earlier safety worries and focus on improving patient uptake and liquidity.
See our latest analysis for Soleno Therapeutics.
That fresh vote of confidence comes after a steady rebuild in sentiment, with a 1 year to date share price return of 13.76% and a remarkable 3 year total shareholder return of 2710.81%. This suggests momentum is...